Lyell Immunopharma, Inc. (LYEL): Nasdaq/NYSE listing notice — Lyell Immunopharma receives Nasdaq delisting notice for bid price below $1.00

Lyell Immunopharma, Inc.

Notice received Jan 23, 2025: common stock bid price below $1.00 for 33 consecutive business days.
Company has 180 calendar days, until July 22, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
If not compliant by July 22, may qualify for an additional 180-day period by transferring to Nasdaq Capital Market.
Company will evaluate options, including a reverse stock split, to cure the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar da

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec

View on SEC.gov

Browse all listing & compliance notices →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-012249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.